Drug or treatment
Alirocumab clinical trials
As of November 12, 2026, Find a Trial lists 6 clinical trials of Alirocumab that are recruiting, at sites in 4 countries (most in United States (3), Slovenia (1), Switzerland (1)). By phase: Phase 2 (1), Phase 4 (1), Phase 1 (1), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 6Clinical trials
- 4Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance | Phase 4 | Ljubljana | Recruiting | May 12, 2026 |
| Long-term use of inclisiran, evolocumab, and alirocumab in real-world care | — | Basel | Recruiting | Apr 22, 2026 |
| Adherence, persistence, and real-life effectiveness of alirocumab 300 mg for people with high cholesterol in Italy | — | Naples, Napoli | Recruiting | Jan 29, 2026 |
| Neoadjuvant chemotherapy for non-small cell lung cancer | Phase 2 | Durham, North Carolina | Recruiting | Apr 26, 2024 |
| Effects of alirocumab on liver health in heavy drinkers | Phase 1 | Bethesda, Maryland | Recruiting | Mar 4, 2021 |
| Alirocumab for people on stable dialysis | Phase 3 | Dallas, Texas | Recruiting | Mar 29, 2018 |
All recruiting trials (6)
-
Dual PCSK9 Inhibition in secondary prevention for high LDL-C with statin intolerance
This study tests whether combining inclisiran and alirocumab lowers LDL cholesterol better than either drug alone in people with ASCVD who can’t tolerate statins.
-
Long-term use of inclisiran, evolocumab, and alirocumab in real-world care
This study tests whether people with high cholesterol medications stick with their PCSK9 inhibitors and inclisiran over the long term in everyday clinical practice.
-
Adherence, persistence, and real-life effectiveness of alirocumab 300 mg for people with high cholesterol in Italy
This project will test whether alirocumab 300 mg helps people with high cholesterol in Italy stick with their treatment and lower their cholesterol when used in routine care.
-
Neoadjuvant chemotherapy for non-small cell lung cancer
This study is testing if adding a new drug called alirocumab to standard chemotherapy helps people with early-stage non-small cell lung cancer have better results after surgery.
-
Effects of alirocumab on liver health in heavy drinkers
This study is testing if the drug alirocumab is safe for heavy drinkers aged 21 to 65 and if it can help improve their liver health.
-
Alirocumab for people on stable dialysis
This study tests whether alirocumab can safely lower cholesterol in adults on stable hemodialysis or peritoneal dialysis over 12 weeks.
Quick answers
How many clinical trials of Alirocumab are recruiting right now?
6, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 4 countries. The most sites are in United States (3 trials), Slovenia (1 trial), Switzerland (1 trial), Italy (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 1, Phase 4: 1, Phase 1: 1, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.